biostudies-literatureUnknown9Hoshino K<b>Introduction:</b> Post-synaptic dopamine receptor supersensitivity (DARSS) has been extensively researched by Dr. Masaya Segawa, who has investigated the efficacy of very-low-dose levodopa therapy (VLDT; 0.5-1 mg/kg/day). Considerable Japanese research supports the possibility that VLDT could be used to treat pediatric neurological disorders. We conducted an on-line survey in 2014 to collect real-world data on the use of VLDT to treat DARSS. <b>Methods:</b> A two-step survey, including a screening test and questionnaire, was posted on a private internet site that could be accessed via the VLDT Research Group home page, and 1,165 pediatric neurologists across Japan were invited to complete it. <b>Results:</b> A total of 25 respondents reported prescribing VLDT; 19 used VLDT to treat autiFrontiers in pediatrics569594https://www.ebi.ac.uk/biostudies/studies/S-EPMC7970027biostudies-literatureVery-Low-Dose Levodopa Therapy for Pediatric Neurological Disorders: A Preliminary Questionnaire in Japan.PMC7970027Nezu AHoshino KYasuhara AKimura KHayashi MIshizaki AKubota MfalseVery-Low-Dose Levodopa Therapy for Pediatric Neurological Disorders: A Preliminary Questionnaire in Japan.<b>Introduction:</b> Post-synaptic dopamine receptor supersensitivity (DARSS) has been extensively researched by Dr. Masaya Segawa, who has investigated the efficacy of very-low-dose levodopa therapy (VLDT; 0.5-1 mg/kg/day). Considerable Japanese research supports the possibility that VLDT could be used to treat pediatric neurological disorders. We conducted an on-line survey in 2014 to collect real-world data on the use of VLDT to treat DARSS. <b>Methods:</b> A two-step survey, including a screening test and questionnaire, was posted on a private internet site that could be accessed via the VLDT Research Group home page, and 1,165 pediatric neurologists across Japan were invited to complete it. <b>Results:</b> A total of 25 respondents reported prescribing VLDT; 19 used VLDT to treat auti2021-01-01T00:00:00Z20212025-04-04T22:01:01.4Z2025-04-04T22:01:01.4ZS-EPMC79700273374803610.3389/fped.2021.569594